Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Andrea Casadei‐Gardini, Margherita Rimini, Toshifumi Tada, +80

European Journal of Cancer

OncologyHepatologyMedicinePathologyBevacizumab Versus Lenvatinib +6

Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma

Fujimasa Tada, Masanori Abe, Masashi Hirooka, +8

International Journal of Oncology

Phase I/ii StudyImmunologyImmunoeditingPathologyImmunodominance +23

Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases

Hironori Ochi, Masashi Hirooka, Yohei Koizumi, +7

Hepatology

Predictors of hepatocellular carcinoma occurrence after direct‐acting antiviral therapy in patients with hepatitis C virus infection

Takao Watanabe, Yoshio Tokumoto, Kouji Joko, +11

Hepatology Research

B cell-activating factor is associated with the histological severity of nonalcoholic fatty liver disease

Teruki Miyake, Masanori Abe, Yoshio Tokumoto, +10

Hepatology International

ImmunologyPathologyFatty Liver DiseaseB Cell-activating FactorCirrhosis +17

Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

Mara Persano, Margherita Rimini, Toshifumi Tada, +76

European Journal of Cancer

B Cell‐Activating Factor Controls the Production of Adipokines and Induces Insulin Resistance

Maho Hamada, Masanori Abe, Teruki Miyake, +6

Obesity

Visceral Adipose TissueImmunologyMetabolic RemodelingImmune SystemAdipokines +19

Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease

Teruki Miyake, Sakiko Yoshida, Shinya Furukawa, +13

Open Medicine

Nonalcoholic Fatty Liver Disease: Portal Hypertension Due to Outflow Block in Patients without Cirrhosis

Masashi Hirooka, Yohei Koizumi, Teruki Miyake, +6

Radiology

Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients

Margherita Rimini, Mara Persano, Toshifumi Tada, +65

Journal of Cancer Research and Clinical Oncology

Survival OutcomesOncologyHepatologyPathologyBevacizumab Versus Lenvatinib +4